Press release from Companies
Published: 2019-03-11 08:07:05
Scandion Oncology A/S (Scandion Oncology) hereby announces that Scandion Oncology, together with University of Copenhagen, has discovered that a number of Scandion Oncology’s compounds are able to overcome antibiotic resistance in bacterial infections through a new mechanism of action. These are findings from preclinical studies. The discovery may pave the way for new drugs for treatment of antibiotic resistance. Scandion Oncology has filed a patent application and owns all rights to this invention. Scandion Oncology is currently exploring the commercial opportunities for these novel findings, since the market for these types of drugs is significant. The outcome of the exploration of the commercial opportunities will weigh in on Scandion Oncology’s decision on how the indication should be further advanced. Scandion Oncology continues to have a strict focus on drug resistance in oncology, but sees this new discovery as a very interesting complement to the Scandion Oncology portfolio. Presently, the Scandion Oncology efforts within antibiotic resistance only requires small-scale resources.
Antibiotic resistance is globally spreading at high levels and the ability to treat common infectious diseases is threatened by new resistance mechanisms. There are a growing number of infections that are becoming more and more difficult or sometimes impossible to treat, as bacteria are quick to develop resistance to antibiotic treatment. CEO of Scandion Oncology, Nils Brünner: “Antibiotic resistance, threatening our ability to treat common infectious diseases, is a huge problem that is rising all over the world. Our discovery shows that some of our compounds can overcome antibiotic resistance and is therefore a discovery of great potential importance.” Professor Brünner continues: “The area of antibiotic resistance complements Scandion Oncology’s existing drug development efforts since it concerns how cells/bacteria can develop resistance to treatment. Scandion Oncology finds it particularly interesting that bacteria and cancer cells apparently share ways to become drug resistant. Although Scandion Oncology’s efforts within this field will not presently require any significant resources, the discovery opens up new commercial opportunities for our company. Therefore, we intend to explore these interesting findings while we continue our strict focus on developing SCO-101 for treatment of anti-cancer drug resistance.” For further information regarding Scandion Oncology, please contact: Nils Brünner, CEO Phone: +45 26 14 47 08 E-mail: nb@scandiononcology.com Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing and tackling one of the greatest challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical animal studies, the company’s leading candidate drug, SCO-101, has been found to significantly enhance the efficacy of certain standard cancer treatments when given in combination. It has been shown in in vitro-studies that SCO-101 restores chemotherapy sensitivity in resistant cells. Scandion Oncology was listed on Spotlight, Sweden in November 2018.
